TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34472117

Group type: EXPERIMENTAL
Intervention: Vatinoxan (0.1 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 12
Study: 32861668

Group type: EXPERIMENTAL
Intervention: EX2 (5 times a week, twice daily, 50 sessions; n=286)
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: EX1 (5 times a week, once daily, 25 sessions; n=272)
Number of subjects: 641

Group type: COMPARATOR
Intervention: CON (low-intensity standard care, 25 sessions; n=83)
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: EX2 and EX1
Number of subjects: 641
Study: 35944766

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Adjusted mortality in N‐E
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Adjusted mortality in S‐E
Number of subjects: 1800
Study: 33852251

Group type: EXPERIMENTAL
Intervention: CAL/BDP cream
Number of subjects: 796

Group type: COMPARATOR
Intervention: CAL/BDP TS
Number of subjects: 796

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 796
Study: 34244250

Group type: EXPERIMENTAL
Intervention: oXiris membrane used on the Prismaflex device at blood pump flow of 450 mL/min during cardiac surgery under CPB
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard cardiac surgery under CPB without oXiris membrane
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: oXiris membrane
Number of subjects: 70
Study: 36343597

Group type: EXPERIMENTAL
Intervention: Viewing low calorie, aesthetically pleasing foods on Instagram
Number of subjects: 436

Group type: COMPARATOR
Intervention: Control condition featuring travel images
Number of subjects: 436
Study: 34106240

Group type: EXPERIMENTAL
Intervention: Measurement-based matching to good-fitting therapists
Number of subjects: 218

Group type: COMPARATOR
Intervention: Case assignment as usual (CAU)
Number of subjects: 218
Study: 35294415

Group type: EXPERIMENTAL
Intervention: Vonoprazan 20mg once-daily
Number of subjects: 81

Group type: COMPARATOR
Intervention: Lansoprazole 30mg once-daily
Number of subjects: 81
Study: 32774912

Group type: EXPERIMENTAL
Intervention: Diltiazem (60 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Nifedipine (10 mg)
Number of subjects: 42
Study: 34085549

Group type: EXPERIMENTAL
Intervention: Intradermal mesotherapy
Number of subjects: 148

Group type: COMPARATOR
Intervention: Intravenous dexketoprofen
Number of subjects: 148
Study: 33276738

Group type: EXPERIMENTAL
Intervention: Cigarette smoking status (current smokers at baseline)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: HCV treatment adherence
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: HCV treatment completion
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Sustained virologic response (SVR)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cigarette smoking after HCV treatment
Number of subjects: 150
Study: 35588897

Group type: EXPERIMENTAL
Intervention: Olpasiran 10 mg q12 weeks
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Olpasiran 75 mg q12 weeks
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Olpasiran 225 mg q12 weeks
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Olpasiran 225 mg q24 weeks
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study: 33677724

Group type: EXPERIMENTAL
Intervention: Open Outpatient Clinic Programme (OOCP)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Traditional Scheduled Routine Follow-up (TSRF)
Number of subjects: 239
Study: 36047138

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 32423694

Group type: EXPERIMENTAL
Intervention: Pharmacist-led 5-step deprescribing intervention
Number of subjects: 295

Group type: COMPARATOR
Intervention: Active waitlist control
Number of subjects: 295
Study: 33416226

Group type: EXPERIMENTAL
Intervention: Sequential Splints Method
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no early orthodontics)
Number of subjects: 45
Study: 35536844

Group type: EXPERIMENTAL
Intervention: Robotic gait training (RGT) using the Ekso robotic exoskeleton
Number of subjects: 128

Group type: COMPARATOR
Intervention: Usual care gait training (UC) using traditional approaches such as manually assisted overground gait training and body weight–supported treadmill training (BWSTT)
Number of subjects: 128
Study: 33886949

Group type: COMPARATOR
Intervention: Matrix support for six months, including face‐to‐face educational activities for health teams.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no matrix support).
Number of subjects: 0
Study: 36227234

Group type: EXPERIMENTAL
Intervention: Rest Redistribution with Heavier Loads (RR + L): 4 sets of (2 × 5) repetitions with 90-second interset rest and 30-second intraset rest using 75% BS 1RM
Number of subjects: 8

Group type: COMPARATOR
Intervention: Traditional Sets (TS): 4 sets of 10 repetitions with 120-second interset rest using 70% BS 1RM
Number of subjects: 8
Study: 33785496

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 213

Group type: COMPARATOR
Intervention: Physiotherapist-led exercise therapy
Number of subjects: 213
Study: 32065775

Group type: EXPERIMENTAL
Intervention: Blood pressure-lowering medication
Number of subjects: 47841

Group type: EXPERIMENTAL
Intervention: Lipid-lowering medications
Number of subjects: 47841

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy
Number of subjects: 47841

Group type: EXPERIMENTAL
Intervention: Any CVD prevention medication
Number of subjects: 47841

Group type: EXPERIMENTAL
Intervention: Blood pressure control
Number of subjects: 47841

Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein cholesterol control
Number of subjects: 47841

Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 47841

Group type: EXPERIMENTAL
Intervention: Physical activity targets
Number of subjects: 47841

Group type: EXPERIMENTAL
Intervention: Blood pressure control in high CVD risk
Number of subjects: 47841

Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein cholesterol control in high CVD risk
Number of subjects: 47841

Group type: EXPERIMENTAL
Intervention: Bodyweight control in high CVD risk
Number of subjects: 47841

Group type: EXPERIMENTAL
Intervention: Blood pressure-lowering medication use in high CVD risk
Number of subjects: 47841
Study: 35157768

Group type: EXPERIMENTAL
Intervention: Mass spectrometry (EXENT&FLC‐MS)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Immunofixation (IFE)
Number of subjects: 223
Study: 32350058

Group type: EXPERIMENTAL
Intervention: PFO closure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical therapy alone (antiplatelet medication such as aspirin or anticoagulation)
Number of subjects: 0
Study: 36401465

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Group D)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (Group N)
Number of subjects: 40
Study: 34896053

Group type: EXPERIMENTAL
Intervention: Microlearning module (MLM)
Number of subjects: 113

Group type: COMPARATOR
Intervention: WISE‐MD™ module
Number of subjects: 113

Group type: COMPARATOR
Intervention: Comparison of post-test1 scores
Number of subjects: 113

Group type: COMPARATOR
Intervention: Pre-test and post-test2 scores comparison
Number of subjects: 113
Study: 32901302

Group type: EXPERIMENTAL
Intervention: Fasting for at least 4 hours
Number of subjects: 2091

Group type: COMPARATOR
Intervention: Non-fasting (unrestricted consumption of liquids and solids)
Number of subjects: 2091

Group type: EXPERIMENTAL
Intervention: Fasting for at least 4 hours (subgroup analysis)
Number of subjects: 2091

Group type: COMPARATOR
Intervention: Non-fasting (unrestricted consumption of liquids and solids) (subgroup analysis)
Number of subjects: 2091
Study: 32042286

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 50 µg once daily
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 34510025

Group type: EXPERIMENTAL
Intervention: Interval stair climbing (moderate‐ to high‐intensity)
Number of subjects: 28
Study: 32659777

Group type: EXPERIMENTAL
Intervention: Glucomannan 0.4%
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Glucomannan 0.8%
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (0% glucomannan)
Number of subjects: 25
Study: 33129848

Group type: COMPARATOR
Intervention: tDCS (anodal, cathodal, or sham) for 20 min at 2 mA over the left dorsolateral prefrontal cortex (lDLPFC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: tDCS (cathodal)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: tDCS (anodal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0
Study: 34763937

Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg daily until progression or treatment discontinuation
Number of subjects: 59
Study: 34494113

Group type: EXPERIMENTAL
Intervention: BEP supplement
Number of subjects: 470

Group type: COMPARATOR
Intervention: Control group (daily iron‐folic acid tablet)
Number of subjects: 470
Study: 33955348

Group type: EXPERIMENTAL
Intervention: Almond consumption (1.5 oz daily with breakfast and as an afternoon snack)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group (habitual breakfast and afternoon snack routines)
Number of subjects: 134
Study: 33595634

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (200,000 IU)
Number of subjects: 240
Study: 36349973

Group type: EXPERIMENTAL
Intervention: Supplementary food and anti-infective treatments
Number of subjects: 1431
Study: 34515108

Group type: EXPERIMENTAL
Intervention: Fully adjusted Doppler standards
Number of subjects: 4505

Group type: COMPARATOR
Intervention: GA-only-adjusted standards
Number of subjects: 4505
Study: 32767064

Group type: EXPERIMENTAL
Intervention: Laparoscopic sacrocolpopexy/cervicopexy (LSC‐Cx)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Anterior vaginal mesh (AVM)
Number of subjects: 120
Study: 32975829

Group type: EXPERIMENTAL
Intervention: Portable gluten sensor (low, medium, and high numbers of single-use capsules)
Number of subjects: 30
Study: 36203046

Group type: EXPERIMENTAL
Intervention: Twice daily (b.i.d.) dexamethasone 0.1%/netilmicin 0.3% (Netildex) ophthalmic gel
Number of subjects: 168

Group type: COMPARATOR
Intervention: Four times daily (q.i.d.) dexamethasone 0.1%/netilmicin 0.3% (Netildex) eye drops
Number of subjects: 168
Study: 34278611

Group type: EXPERIMENTAL
Intervention: ZOL 5-mg infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 35799973

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive-behavioral therapy
Number of subjects: 200
Study: 32286906

Group type: EXPERIMENTAL
Intervention: Brief nurse intervention using visual materials
Number of subjects: 220

Group type: COMPARATOR
Intervention: Brief nurse intervention using verbal descriptions
Number of subjects: 220
Study: 33704353

Group type: EXPERIMENTAL
Intervention: Ablative radiation therapy (A‐RT) at 98 Gy biologically effective dose
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Ablative radiation therapy (A‐RT)
Number of subjects: 119
Study: 32041661

Group type: EXPERIMENTAL
Intervention: Prepectoral implant placement
Number of subjects: 70

Group type: COMPARATOR
Intervention: Subpectoral implant placement
Number of subjects: 70
Study: 35277771

Group type: EXPERIMENTAL
Intervention: eTEP repair
Number of subjects: 60
Study: 34014693

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral couple therapy (CBCT)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Topical lidocaine
Number of subjects: 108
Study: 32379683

Group type: EXPERIMENTAL
Intervention: Bergamot orange essence (2 drops of 3%)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Odourless grape seed oil (control group, 2 drops)
Number of subjects: 60
Study: 35165478

Group type: EXPERIMENTAL
Intervention: Mechanical submucosal debridement using titanium curettes combined with glycine powder air-polishing
Number of subjects: 28

Group type: COMPARATOR
Intervention: Mechanical submucosal debridement using titanium only (Control)
Number of subjects: 28
Study: 32965691

Group type: EXPERIMENTAL
Intervention: Higher MAP (90 mm Hg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lower MAP (60 mm Hg)
Number of subjects: 24
Study: 34554814

Group type: EXPERIMENTAL
Intervention: mHealth intervention (text message reminders)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care arm
Number of subjects: 0
Study: 32470217

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Mometasone nasal irrigation
Number of subjects: 43
Study: 34014490

Group type: EXPERIMENTAL
Intervention: BE-infused digital outreach materials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard outreach materials (implied control)
Number of subjects: 0
Study: 32485785

Group type: EXPERIMENTAL
Intervention: Plerixafor
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 36451139

Group type: EXPERIMENTAL
Intervention: EMDR (Eye Movement Desensitization and Reprocessing) therapy, 3 to 5 sessions
Number of subjects: 4
Study: 35694079

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 75

Group type: COMPARATOR
Intervention: Inhalation groups (Desflurane, Propofol, Sevoflurane)
Number of subjects: 75
Study: 34706456

Group type: EXPERIMENTAL
Intervention: Active Cranial Electrotherapy Stimulation (CES) with in-ear electrodes (10 Hz frequency, 500 μA intensity) for 3 weeks, 20 trials at home.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham group (placebo control).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active Cranial Electrotherapy Stimulation (CES) with in-ear electrodes.
Number of subjects: 0
Study: 36102255

Group type: EXPERIMENTAL
Intervention: Highest quartile of plasma YKL‐40 levels
Number of subjects: 3377

Group type: EXPERIMENTAL
Intervention: Each SD increase in log-transformed YKL‐40 level
Number of subjects: 3377

Group type: EXPERIMENTAL
Intervention: Adding YKL‐40 to a model with conventional risk factors
Number of subjects: 3377

Group type: EXPERIMENTAL
Intervention: YKL‐40 levels
Number of subjects: 3377
Study: 32585039

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (7.5 mg/kg body weight)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 36136760

Group type: EXPERIMENTAL
Intervention: Combined bOPV + OCV
Number of subjects: 579

Group type: COMPARATOR
Intervention: bOPV-only
Number of subjects: 579

Group type: COMPARATOR
Intervention: OCV-only
Number of subjects: 579
Study: 33675631

Group type: EXPERIMENTAL
Intervention: EMA401 100 mg b.i.d.
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: EMA401 25 mg b.i.d.
Number of subjects: 266

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study: 32769535

Group type: EXPERIMENTAL
Intervention: Preoperative interobserver measurements on pelvic radiographs
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Preoperative interobserver measurements on CT images
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Postoperative interobserver measurements on pelvic radiographs
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Postoperative interobserver measurements on CT images
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Preoperative intraobserver measurements on pelvic radiographs
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Preoperative intraobserver measurements on CT images
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Postoperative intraobserver measurements on pelvic radiographs
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Postoperative intraobserver measurements on CT images
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intraoperative fluoroscopy measurements
Number of subjects: 60
Study: 34112040

Group type: EXPERIMENTAL
Intervention: Intimacy condition (self-disclosure and shared values)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Information condition (discussing information from an article about climate change)
Number of subjects: 0
Study: 32032416

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery with concentrated growth factor (CGF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No surgery (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery with CGF
Number of subjects: 40
Study: 35363203

Group type: EXPERIMENTAL
Intervention: Tuina (TN)
Number of subjects: 612

Group type: COMPARATOR
Intervention: Physiotherapy (PT)
Number of subjects: 612

Group type: COMPARATOR
Intervention: Tuina combined with Physiotherapy (TN + PT)
Number of subjects: 612
Study: 35510597

Group type: EXPERIMENTAL
Intervention: Awakening from REM sleep
Number of subjects: 20

Group type: COMPARATOR
Intervention: Awakening from stage N1/N2 sleep
Number of subjects: 20
Study: 34609381

Group type: EXPERIMENTAL
Intervention: Checklist user interface for the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: DC/TMD diagnostic decision trees (control tool)
Number of subjects: 0
Study: 32250530

Group type: EXPERIMENTAL
Intervention: Lyo avexitide (exendin 9-39) at ascending doses, administered SC twice daily for 3 days
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Liq avexitide (exendin 9-39) at a fixed dose of 30 mg, administered SC twice daily for 3 days
Number of subjects: 19
Study: 35039301

Group type: EXPERIMENTAL
Intervention: Betamethasone valerate ointment (5 times a day)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (usual oral hygiene guidance only)
Number of subjects: 102
Study: 34273797

Group type: EXPERIMENTAL
Intervention: Mobile application (MA)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control
Number of subjects: 62
Study: 33543283

Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham tDCS/AE
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: tDCS/AE
Number of subjects: 10
Study: 32299482

Group type: COMPARATOR
Intervention: Etoricoxib alone (Control group)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate plus etoricoxib (Experimental group)
Number of subjects: 106
Study: 36474794

Group type: EXPERIMENTAL
Intervention: 12-week multimodal intervention (targeted nutrition, progressive resistance exercise, arthritis self-management support)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 12-week multimodal intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 33392944

Group type: EXPERIMENTAL
Intervention: Transscleral cyclophotocoagulation with MicroPulse® laser (3000 mW)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ahmed valve implantation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 35765222

Group type: EXPERIMENTAL
Intervention: RT001 (2.88 g/day, increased to 8.64 g/day as tolerated)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: RT001 (5.6 ± 1.6 g/day; dose range, 1.92 to 8.64 g/day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: RT001
Number of subjects: 16
Study: 32648776

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Prebiotics
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Growing-up milk
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Kiwi
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Garlic
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Xylitol
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Elderberry
Number of subjects: 33
Study: 34389633

Group type: EXPERIMENTAL
Intervention: GSK2982772 60 mg three times daily for 42 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo/open-label GSK2982772
Number of subjects: 36
Study: 33040948

Group type: EXPERIMENTAL
Intervention: Dry needling added to standard care
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 20
Study: 34110859

Group type: EXPERIMENTAL
Intervention: Leading questions
Number of subjects: 1182

Group type: EXPERIMENTAL
Intervention: Elaborate leading questions
Number of subjects: 1182

Group type: EXPERIMENTAL
Intervention: Doctored photographs
Number of subjects: 1182

Group type: EXPERIMENTAL
Intervention: Simple narratives
Number of subjects: 1182

Group type: EXPERIMENTAL
Intervention: Scrambled narratives
Number of subjects: 1182

Group type: EXPERIMENTAL
Intervention: Missing word narratives
Number of subjects: 1182
Study: 32163323

Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal (CR) when fully rested
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive reappraisal (CR) after sleep deprivation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neural responses to negative images under sleep deprivation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative affect ratings and heart rate deceleration under sleep deprivation
Number of subjects: 0
Study: 33823211

Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy (VL)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 204
Study: 34075199

Group type: EXPERIMENTAL
Intervention: Maximum fluorescein tear break-up time (FTBUTmax)
Number of subjects: 147
Study: 33357510

Group type: COMPARATOR
Intervention: Intravenous carboplatin (AUC5 or AUC6) and intravenous paclitaxel (175 mg/m2) on day 1 of every 21‐day cycle (control group)
Number of subjects: 779

Group type: EXPERIMENTAL
Intervention: Intravenous carboplatin (AUC5 or AUC6) on day 1 and intravenous dose‐fractionated paclitaxel (80 mg/m2) on days 1, 8, and 15 of every 21‐day cycle (group 2)
Number of subjects: 779

Group type: EXPERIMENTAL
Intervention: Intravenous dose‐fractionated carboplatin (AUC2) and intravenous dose‐fractionated paclitaxel (80 mg/m2) on days 1, 8, and 15 of every 21‐day cycle (group 3)
Number of subjects: 779
Study: 32474130

Group type: EXPERIMENTAL
Intervention: 5-session telephone-administered motivational interviewing plus behavioral skills training (teleMI+BST)
Number of subjects: 336

Group type: COMPARATOR
Intervention: 5-session telephone-administered coping effectiveness training (teleCET)
Number of subjects: 336
Study: 32186013

Group type: EXPERIMENTAL
Intervention: Jiawei Xiaoyao (JWXY) capsules
Number of subjects: 210

Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 210